<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415883</url>
  </required_header>
  <id_info>
    <org_study_id>CVNP489A2106</org_study_id>
    <nct_id>NCT00415883</nct_id>
  </id_info>
  <brief_title>To Compare the Blood Level of Marketed Japanese Valsartan Tablet Formulation vs Global Valsartan Tablet Formulation in Healthy Volunteers</brief_title>
  <official_title>An Open-Label, Randomized, Single Dose, Two Period, Crossover Study to Determine the Relative Bioavailability of Valsartan 160 mg Japanese Formulation and Valsartan 160 mg Global Formulation in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess how the body changes the blood level of single dose of
      valsartan 160 mg tablet Japanese formulation and valsartan 160 mg tablet global formulation
      under fasting condition in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative bioavailability of valsartan 160 mg Japanese formulation and valsartan 160 mg global formulation under fasting conditions in healthy adult volunteers</measure>
  </primary_outcome>
  <enrollment>40</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, male or female subjects age 18 to 45 years of age (inclusive)

          -  In good health

          -  Female subjects either surgically sterilized at least 6 months prior to study
             participation or post-menopausal (no regular menstrual bleeding for at least 2 years)

          -  Body mass index within the range of 18.5 to 28 kg/m2 and weigh at least 45 kg

        Exclusion Criteria:

          -  Smokers

          -  Use prescription drugs within 4 weeks prior dosing, or over-the-counter medication
             (vitamins, herbal supplements, dietary supplements, potassium supplements) within 2
             weeks prior to dosing. Paracetamol is acceptable

          -  Participation in any clinical investigation within 4 weeks prior to dosing

          -  Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing

          -  Significant illness within 2 weeks prior to dosing.

          -  History of clinically significant cardiac abnormalities, fainting, low blood pressure
             upon standing, irregular heartbeats.

          -  History of acute or chronic bronchospastic disease (including asthma and chronic
             obstructive pulmonary disease, treated or untreated).

          -  History of clinically significant drug allergy or history of atopic allergy (asthma,
             urticaria, eczematous dermatitis).

          -  Known hypersensitivity or severe reaction to valsartan or similar drugs

          -  Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism or excretion of drugs or which may jeopardize the subject in
             case of participation in the study.

          -  History of immunodeficiency diseases, including a positive HIV (ELISA and Western
             blot) test result.

          -  A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.

          -  History of drug or alcohol abuse within the 6 months prior to dosing

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2006</study_first_submitted>
  <study_first_submitted_qc>December 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2006</study_first_posted>
  <last_update_submitted>June 21, 2007</last_update_submitted>
  <last_update_submitted_qc>June 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2007</last_update_posted>
  <keyword>Relative bioavailability, formulation, Japanese, valsartan, healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

